围绕络病理论研究的三大理论框架"络病证治""脉络学说""气络学说"，出版发行了《络病学》《脉络论》《气络论》三本 专著，《络病学》英文版教材在弗吉尼亚整合医学大学、加拿大安大略中医学院、新加坡中医学院等40余所海外教育机构开 课。这些研究平台的搭建和理论成果的传播，不仅使络病理论走向国际，也更助力了国际中医药人才的培养。 11月22日，第二十一届国际络病学大会海外论坛在越南河内举行，此次论坛由世界中医药学会联合会络病专业委员会、越 南南医协会共同主办，来自越南、中国、泰国、罗马尼亚等国家和地区的专家学者，围绕络病理论的临床应用以及科研进展进 行交流分享，展示络病学研究和学科建设取得的优秀成果，以进一步推动中医药高质量发展和走向世界。 从会上获悉，在络病理论指导下，研制出的17个通络药物已在50多个国家和地区注册上市。络病理论何以拥有如此强大的 生命力？能在全球掀起医学界的浪潮？ 中国驻越南大使馆邬国权公参在致辞中表示："今年是中越建交75周年暨人文交流年，传统医药交流作为两国重要的载 体，以本次络病大会海外论坛为纽带深化合作，可谓恰逢其时，意义非凡。越南传统医药与中医药源相近，中国在该领域处于 世界领先地位， ...

以岭药业专利中药全球注册情况 "走出去"：理论先行，科技破局，让中医药惠及世界 11月22日，来自越南、泰国、中国、加拿大等国家和地区的专家学者齐聚一堂，围绕络病理论的最新科 研进展展开深入交流，共商中医药现代化与国际化发展路径。 第二十一届国际络病学大会海外论坛在越南举行 "走出去"是中医药国际化的关键起点。以岭药业深知，中医药要走向世界，理论必须先行。33年来，企 业以"科技创新，成果转化，产业发展"为核心发展战略，系统构建了络病理论体系。该体系被国医大师 路志正评价为"中医络病学发展史上的第四个里程碑"。 以岭医药研究院中医药分院副院长、络病研究部主任李红蓉博士在采访时介绍称，以岭药业从"络病证 治"到"脉络学说"再到"气络学说"，搭建完成了络病研究三大理论框架，相关专著如《络病学》《脉络 论》《气络论》已出版发行，为中医络病学学科发展奠定了坚实的理论基础，《络病学》英文版教材在 弗吉尼亚整合医学大学、加拿大安大略中医学院、新加坡中医学院等海外教育机构开课，助力国际中医 药人才培养。以岭药业在该理论指导下继承创新，创立了"理论+临床+新药+实验+循证"一体化的中医 学术创新与转化新模式。 基于坚实的络病 ...

越南南医协会主席张越平致辞时指出，络病理论是非常重要的一个理论，国际络病学大会作为该领域的 重要学术平台，多年来始终引领着络病学研究的前沿方向，推动着理论创新与临床实践的深度融合。 "我们欣喜地看到络病理论在现代科学的验证下不断焕发新的生机，其系统性的思维方式，在防治心脑 血管疾病、糖尿病等疾病方面展现出的独特疗效，这为包括越南传统医学在内的各国传统医学的现代化 发展提供了成功的范例。"张越平表示，希望未来能与中国及各国的研究机构建立更加亲密的合作伙伴 关系，共同开展络病学术研究与信息共享。 越南传统医药大学副校长段光辉致辞时表示，络病学说日益完善，创新成果不断发展，为全球传统医学 的现代化贡献了巨大的科学潜力。作为越南一所国家重点院校，越南传统医药大学始终致力于将络病学 研究成果融入教学，培养与科研体系中鼓励教师与学生深入学习研究络病学，为推动传统医学创新发展 贡献力量。 中医络病理论体系可追溯至春秋战国时期，《黄帝内经》首次提出"经脉""经络""血脉""络脉""络病"概 念及络病治疗。东汉张仲景在《伤寒杂病论》首次提出"脉络"，创立通络治疗方药。清代叶天士进一步 提出"久病入络""久痛入络"，发展络病治疗 ...

Core Viewpoint - The release of the first expert consensus on the cardiovascular event chain provides a Chinese characteristic clinical drug treatment plan that integrates traditional Chinese medicine and Western medicine, aiming to systematically intervene in cardiovascular diseases [1][2][3] Group 1: Expert Consensus Overview - The expert consensus titled "Expert Consensus on Systematic Intervention of Cardiovascular Event Chain with Tongluo Drugs" was published during the 12th Chinese Association of Integrative Medicine Vascular Disease Conference [1] - The consensus addresses the need for new intervention methods for the cardiovascular event chain, which is characterized by a series of events leading to severe outcomes such as myocardial infarction and heart failure [1] Group 2: Mechanisms and Clinical Evidence - The consensus includes a series of Tongluo drugs (e.g., Jinlida granules, Tongxinluo capsules) and their mechanisms and clinical evidence for intervening in diseases related to the cardiovascular event chain, such as diabetes, stroke, coronary heart disease, arrhythmia, and heart failure [2] - Significant clinical evidence from national key research projects supports the breakthroughs in traditional Chinese medicine, including the prevention of type 2 diabetes and improvements in coronary plaque stability [2] Group 3: Impact and Future Prospects - The consensus is expected to enhance the prevention and treatment of cardiovascular diseases, significantly reducing their incidence and mortality rates [3] - The release of the consensus is anticipated to attract global attention to traditional Chinese medicine and stimulate further research in the integration of traditional and modern medical practices [3]

Core Viewpoint - Yiling Pharmaceutical reported a net loss for 2024 due to revenue reduction from expiring respiratory products and increased inventory impairment, but maintains high R&D investment levels, with over 900 million yuan allocated, representing 13.94% of revenue, which is leading in the industry [1][5]. R&D Investment - Yiling Pharmaceutical has a strong R&D capability based on its unique theory of network disease, which has led to a nearly 25-fold increase in R&D investment since 2008 [2]. - The company continues to maintain high R&D investment levels, with 900 million yuan in 2024, ranking among the top in the industry [5]. Product Development and Pipeline - The company has 17 patented new drugs, with 11 included in the national medical insurance directory and 5 in the national essential drug list [5]. - Yiling Pharmaceutical has ongoing registration applications for two innovative traditional Chinese medicine products and three chemical drug products, enhancing its product pipeline [6]. Market Performance - Yiling Pharmaceutical's respiratory and cardiovascular products lead their respective markets, with Lianhua Qingwen capturing 24.36% of the cold medicine market in public healthcare [7]. - The company’s core cardiovascular products hold a combined market share of 17.69% in the public healthcare sector [7]. New Growth Areas - The company is expanding into the health and wellness sector, with products targeting blood lipid regulation, sleep improvement, and blood sugar control [8]. - Yiling Pharmaceutical's OTC product Baizi Bujin Capsule is highlighted as a potential new pillar product, supported by extensive evidence from clinical studies [8].

Core Insights - The Wuzhen Health Conference held from April 8 to 12 showcased the achievements of Yiling Pharmaceutical in digital transformation and innovation, earning multiple awards including "Top 10 Digital Model Enterprises in Pharmaceutical Manufacturing" and "Top 20 Digital Leading Enterprises in Pharmaceutical Retail" [1][2] Digital Transformation - Yiling Pharmaceutical has over 30 years of experience in traditional Chinese medicine, focusing on integrating digital technologies like big data and artificial intelligence to optimize drug development and accelerate innovation [2] - The company has established a comprehensive digital system covering research, production, and quality control, enhancing product quality and traceability through smart manufacturing and IoT technologies [2] - Yiling has built over 60 medicinal herb cultivation bases across seven major production areas in China, utilizing digital management systems to ensure standardized and sustainable raw material quality [2] Brand Strategy Innovation - Yiling Pharmaceutical emphasizes innovation in its brand strategy, aiming to create a globally influential traditional Chinese medicine brand [3] - The company has developed a series of innovative traditional Chinese medicines guided by the theory of meridian diseases, achieving significant recognition including six national science and technology awards [3] - Products like Tongxinluo capsules and Qiliqiangxin capsules have gained a strong reputation among consumers for treating cardiovascular diseases and other health issues [3] Product Positioning Innovation - Yiling Pharmaceutical focuses on accurately meeting diverse consumer health needs through innovative product positioning [4] - The company’s product, Wanbi'an Suanzaoren Oil Soft Capsules, won the "Soso Rabbit Health Goodies - Preferred Award" for its unique approach to sleep improvement [4] - Research indicates that Suanzaoren oil significantly enhances deep sleep quality and alleviates anxiety without dependency, making it popular among consumers [4] Market Channel Innovation - Yiling Pharmaceutical actively innovates in market channels, expanding beyond traditional sales methods to include online platforms and live-streaming sales [5] - The company promotes the internationalization of traditional Chinese medicine through evidence-based research, with products like Tongxinluo capsules registered in over 50 countries [5] - Yiling's market channel strategy focuses on comprehensive coverage, international breakthroughs, brand synergy, and digital empowerment, transitioning from a traditional pharmaceutical company to a modern, international health service provider [5]